A Study of Axicabtagene Ciloleucel in Participants With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL)

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03105336

Acronym

ZUMA-5

Enrollment

159

Registered

2017-04-07

Start date

2017-06-06

Completion date

2024-12-20

Last updated

2025-12-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Follicular Lymphoma, Indolent Non-Hodgkin Lymphoma, Marginal Zone Lymphoma

Brief summary

The goal of this study is to assess whether axicabtagene ciloleucel improves the clinical outcome in participants with relapsed or refractory indolent non-Hodgkin lymphoma (r/r) iNHL.

Detailed description

After completing at least 60 months (FL participants) or at least 24 months (MZL participants) of assessments in this study since the initial axicabtagene ciloleucel infusion and after agreement by the Sponsor, participants will transition to a long-term follow-up (LTFU) study, KT-US-982-5968 where they will complete the remainder of the 15 year follow-up assessments.

Interventions

BIOLOGICALAxicabtagene ciloleucel

Administered intravenously

DRUGCyclophosphamide

Administered intravenously

DRUGFludarabine

Administered intravenously

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Key Inclusion Criteria: * Individual has follicular lymphoma (FL) or marginal zone lymphoma (MZL) that has progressed after at least 2 lines of treatment with combination chemoimmunotherapy) (e.g. R-bendamustine, R-CHOP). * Individual has (measurable disease). * Individual has no known presence or history of central nervous system (CNS) involvement by lymphoma. * If individual is on conventional systemic therapy or systemic inhibitory/stimulatory immune checkpoint therapy, individual is able to stop conventional therapy 2 weeks or 5 half-lives, whichever is shorter, or immune checkpoint therapy 3 half-lives prior to planned leukapheresis. * Individual has Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 and adequate renal, hepatic, pulmonary, and cardiac function * Individual is not pregnant or breastfeeding (female individuals only) and is willing to use birth control from the time of consent through 12 months following chimeric antigen receptor (CAR) T cell infusion (both male and female individuals). Key

Exclusion criteria

* Transformed FL or MZL * Small lymphocytic lymphoma * Histological Grade 3b FL * Individual will have undergone autologous transplant within 6 weeks of planned leukapheresis or has undergone allogeneic transplant. * Individual has evidence of involvement of the heart by lymphoma or requirement for urgent therapy due to ongoing or impending oncologic emergency (e.g. mass effect, tumor lysis syndrome, etc.) Note: Other protocol defined Inclusion/

Design outcomes

Primary

Measure	Time frame	Description
Objective Response Rate (ORR): Percentage of Participants With Objective Response Per the Lugano Classification by Central Assessment	Up to 85.6 months	OR:CR (complete metabolic response (CMR)+complete radiological response (CRR))+PR (partial MR response (PMR) +partial RR(PRR)).CMR: score 1(no uptake above background)/2(uptake≤mediastinum)/3(uptake \>mediastinum but ≤liver)with/without a residual mass on positron emission tomography 5-point scale;no new lesions,CRR:target nodes/nodal masses regressed to ≤1.5 cm in longest transverse diameter of lesion (LDi);no extralymphatic sites of disease;absent non-measured lesion(NMLs);organ enlargement regress to normal; no new sites;bone marrow normal by morphology.PMR:score 4(uptake moderately\>liver)/5(uptake markedly\>liver, new lesions) with reduced uptake compared with baseline and residual mass;no new lesions;responding disease at interim/residual disease at end of treatment.PRR:≥50% decrease in sum of product of diameters up to 6 target nodes and extra-nodal sites;absent/normal,regressed,but no increase of NMLs;spleen regressed by\>50% in length beyond normal. Percentages were rounded-off.

Secondary

Measure	Time frame	Description
ORR: Percentage of Participants With OR Per the Lugano Classification by Central Assessment Among Participants With 3 or More Lines of Prior Therapy	Up to 85.6 months	OR was defined as percentage of participants with CR + PR per the Lugano Classification for participants with 3 or more lines of prior therapy. CR and PR are defined in OM#1. Percentages were rounded-off.
Percentage of Participants With CR Per Lugano Classification by Central Assessment Among Participants With 3 or More Lines of Prior Therapy	Up to 85.6 months	CR is defined as OM#1. Percentages were rounded-off.
ORR: Percentage of Participants With OR Per the Lugano Classification by Investigator Assessment	Up to 85.6 months	OR was defined as percentage of participants with CR + PR per the Lugano Classification. CR and PR are defined in OM#1. Percentages were rounded-off.
Percentage of Participants With Best Overall Response (BOR) Per the Lugano Classification by Central Assessment	Up to 85.6 months	BOR was defined as percentage of participants with CR, PR, stable disease(SD), disease progression(PD), non-evaluable(NE), undefined/no disease or not done as best response to treatment by the Lugano Classification. CR and PR defined in OM#1. SD/no metabolic response(NMR):score 4(uptake moderately greater than (\>) liver) or 5(uptake markedly\>liver and/ or new lesions) with no significant change in fluorodeoxyglucose(FDG) uptake compared to baseline(screening), at interim time point or end of treatment; no new sites of disease should be observed. PD:score 4(uptake moderately\>liver) or 5(uptake markedly\>liver and/or new lesions) with an increase in intensity of uptake from baseline; new FDG-avid foci consistent with lymphoma at interim or end of treatment assessment; new FDG-avid foci consistent with lymphoma rather than another etiology (eg, infection, inflammation); new or recurrent FDG-avid foci in bone marrow. Not done:no assessment at time of analysis. Percentages were rounded off.
Percentage of Participants With BOR Per the Lugano Classification by Investigator Assessment	Up to 85.6 months	BOR was defined as the percentage of participants with CR, PR, stable disease (SD), PD, NE (not evaluable) or not done as best response to treatment by the Lugano Classification. CR and PR are defined in OM#1. SD, PD and not done are defined in OM#6. Percentages were rounded off.
Duration of Response (DOR) by Central Assessment	Up to 85.6 months	DOR was defined only for participants who experienced an OR (CR and PR) and was the time from the first objective response to disease progression or disease-related death, whichever came first. CR and PR are defined in OM#1. PD is defined in OM#6. Kaplan-Meier (KM) estimates were used for analysis.
DOR by Investigator Assessment	Up to 85.6 months	DOR was defined only for participants who experienced an OR (CR and PR) and was the time from the first objective response to disease progression or disease-related death, whichever came first. Definitions for CR, PR are defined in OM#1. PD is defined in OM#6. KM estimates were used for analysis.
Progression-free Survival (PFS) Per Lugano Classification by Central Assessment	Up to 85.6 months	PFS was defined as the time from the axicabtagene ciloleucel infusion date to the date of disease progression per Lugano classification or death from any cause. PD is defined in OM 6. KM estimates were used for analysis.
PFS Per Lugano Classification by Investigator Assessment	Up to 85.6 months	PFS was defined as the time from the axicabtagene ciloleucel infusion date to the date of disease progression per Lugano classification or death from any cause. PD is defined in OM 6. KM estimates were used for analysis.
Percentage of Participants With CR Per the Lugano Classification by Central Assessment	Up to 85.6 months	CR is defined in outcome measure (OM)#1. Percentages were rounded-off.
Time to Next Therapy	Up to 85.6 months	Time from axicabtagene ciloleucel infusion date to the start of the subsequent new lymphoma therapy or death from any cause. KM estimates were used for analysis.
Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)	Up to 85.6 months	TEAE was defined as any adverse event with onset on or after the start of treatment. Percentages were rounded-off.
Percentage of Participants With Increase in Laboratory Values Reported as Grade 3 or Higher	Up to 85.6 months	Percentages were rounded-off.
Percentage of Participants With Decrease in Laboratory Values Reported as Grade 3 or Higher	Up to 85.6 months	Percentages were rounded-off.
Percentage of Participants With Antibodies Against Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells	Up to 85.6 months	—
Levels of Anti-CD19 CAR T Cells in Blood	Day 7, Week 2, Week 4, Month 3, Month 6, Month 12, Month 18 and Month 24	—
Levels of Serum C-Reactive Protein (CRP)	Baseline (at enrollment), predose: Day 0, postdose: Day 3, Day 7, Week 2, Week 4	—
Levels of Serum Ferritin, Serum ICAM-1, Serum IL-2 R Alpha, Serum Perforin and Serum VCAM-1	Baseline (at enrollment), predose: Day 0, postdose: Day 3, Day 7, Week 2, Week 4	Serum analytes: Serum Ferritin, Serum intercellular adhesion molecule-1 (ICAM-1), Serum interleukin-2 receptor (IL-2 R) alpha, Serum Perforin and Serum vascular cell adhesion molecule-1 (VCAM-1).
Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Baseline (at enrollment), predose: Day 0, postdose: Day 3, Day 7, Week 2, Week 4	Serum analytes: Serum CXCL10, Serum Granzyme B, Serum interferon (IFN)-gamma, Serum IL-1 receptor antagonist (RA), Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum tumor necrosis factor (TNF) Alpha.
Overall Survival (OS)	Up to 85.6	OS was defined as the time from axicabtagene ciloleucel infusion to the date of death. KM estimates were used for analysis.

Countries

France, United States

Participant flow

Recruitment details

Participants were enrolled at study sites in the United States and France.

Pre-assignment details

189 participants were screened. A total of 159 participants were enrolled. However, one participant discontinued the study as the participant did not meet study condition eligibility criteria (was diagnosed with diffuse large B-cell lymphoma (DLBCL)). So, 158 participants were considered in the Full Analysis Set (FAS = all enrolled participants).

Participants by arm

Arm	Count
Axicabtagene Ciloleucel (Follicular Lymphoma) Participants with relapsed or refractory (r/r) B-cell indolent non-Hodgkin lymphoma (iNHL) subtype of follicular lymphoma (FL) received the following treatment during the study: * A conditioning chemotherapy regimen of fludarabine 30 mg/m\^2/day intravenously (IV) and cyclophosphamide 500 mg/m\^2/day IV for 3 days (Day -5 to Day -3). * A single IV infusion at a target dose of 2×10\^6 anti-cluster of differentiation 19 (CD19) chimeric antigen receptor (CAR) transduced autologous T cells/kg on Day 0.	124
Axicabtagene Ciloleucel (Marginal Zone Lymphoma) Participants with r/r B-cell iNHL subtype of marginal zone lymphoma (MZL) received the following treatment during the study: * A conditioning chemotherapy regimen of fludarabine 30 mg/m\^2/day IV and cyclophosphamide 500 mg/m\^2/day IV for 3 days (Day -5 to Day -3). * A single IV infusion at a target dose of 2×10\^6 anti-CD19 CAR transduced autologous T cells/kg on Day 0.	28
Total	152

Withdrawals & dropouts

Period	Reason	FG000	FG001
Overall Study	Death	40	8
Overall Study	Investigator Decision	3	0
Overall Study	Lost to Follow-up	13	2
Overall Study	Reason Not Specified	3	3
Overall Study	Rollover to Longterm Follow-up Study Criteria	61	15
Overall Study	Subject Withdrawal of Consent from Further Follow-up	7	3

Baseline characteristics

Characteristic	Total	Axicabtagene Ciloleucel (Follicular Lymphoma)	Axicabtagene Ciloleucel (Marginal Zone Lymphoma)
Age, Categorical <=18 years	0 Participants	0 Participants	0 Participants
Age, Categorical >=65 years	51 Participants	38 Participants	13 Participants
Age, Categorical Between 18 and 65 years	101 Participants	86 Participants	15 Participants
Age, Continuous	60.0 years STANDARD_DEVIATION 10	59 years STANDARD_DEVIATION 9.9	63 years STANDARD_DEVIATION 9.6
Ethnicity (NIH/OMB) Hispanic or Latino	9 Participants	6 Participants	3 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	142 Participants	118 Participants	24 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	1 Participants	0 Participants	1 Participants
Race/Ethnicity, Customized Race Asian	2 Participants	2 Participants	0 Participants
Race/Ethnicity, Customized Race Black or African American	6 Participants	4 Participants	2 Participants
Race/Ethnicity, Customized Race Other or More Than One Race	4 Participants	3 Participants	1 Participants
Race/Ethnicity, Customized Race White	140 Participants	115 Participants	25 Participants
Region of Enrollment France	10 Participants	10 Participants	0 Participants
Region of Enrollment United States	142 Participants	114 Participants	28 Participants
Sex: Female, Male Female	66 Participants	51 Participants	15 Participants
Sex: Female, Male Male	86 Participants	73 Participants	13 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk	EG003 affected / at risk
deaths Total, all-cause mortality	36 / 127	8 / 31	5 / 14	0 / 2
other Total, other adverse events	123 / 124	28 / 28	13 / 14	2 / 2
serious Total, serious adverse events	65 / 124	19 / 28	5 / 14	1 / 2

Outcome results

Primary

Objective Response Rate (ORR): Percentage of Participants With Objective Response Per the Lugano Classification by Central Assessment

OR:CR (complete metabolic response (CMR)+complete radiological response (CRR))+PR (partial MR response (PMR) +partial RR(PRR)).CMR: score 1(no uptake above background)/2(uptake≤mediastinum)/3(uptake \>mediastinum but ≤liver)with/without a residual mass on positron emission tomography 5-point scale;no new lesions,CRR:target nodes/nodal masses regressed to ≤1.5 cm in longest transverse diameter of lesion (LDi);no extralymphatic sites of disease;absent non-measured lesion(NMLs);organ enlargement regress to normal; no new sites;bone marrow normal by morphology.PMR:score 4(uptake moderately\>liver)/5(uptake markedly\>liver, new lesions) with reduced uptake compared with baseline and residual mass;no new lesions;responding disease at interim/residual disease at end of treatment.PRR:≥50% decrease in sum of product of diameters up to 6 target nodes and extra-nodal sites;absent/normal,regressed,but no increase of NMLs;spleen regressed by\>50% in length beyond normal. Percentages were rounded-off.

Time frame: Up to 85.6 months

Population: Participants in the Full Analysis Set with available data were analyzed. Full Analysis Set consisted of all enrolled participants.

Arm	Measure	Value (NUMBER)
Axicabtagene Ciloleucel (Follicular Lymphoma)	Objective Response Rate (ORR): Percentage of Participants With Objective Response Per the Lugano Classification by Central Assessment	92 percentage of participants
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Objective Response Rate (ORR): Percentage of Participants With Objective Response Per the Lugano Classification by Central Assessment	69 percentage of participants

Secondary

DOR by Investigator Assessment

DOR was defined only for participants who experienced an OR (CR and PR) and was the time from the first objective response to disease progression or disease-related death, whichever came first. Definitions for CR, PR are defined in OM#1. PD is defined in OM#6. KM estimates were used for analysis.

Time frame: Up to 85.6 months

Population: Participants with OR in Full Analysis Set were analyzed.

Arm	Measure	Value (MEDIAN)
Axicabtagene Ciloleucel (Follicular Lymphoma)	DOR by Investigator Assessment	60.4 months
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	DOR by Investigator Assessment	NA months

Secondary

Duration of Response (DOR) by Central Assessment

DOR was defined only for participants who experienced an OR (CR and PR) and was the time from the first objective response to disease progression or disease-related death, whichever came first. CR and PR are defined in OM#1. PD is defined in OM#6. Kaplan-Meier (KM) estimates were used for analysis.

Time frame: Up to 85.6 months

Population: Participants with OR in the Full Analysis Set with available data were analyzed

Arm	Measure	Value (MEDIAN)
Axicabtagene Ciloleucel (Follicular Lymphoma)	Duration of Response (DOR) by Central Assessment	38.6 months
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Duration of Response (DOR) by Central Assessment	NA months

Secondary

Levels of Anti-CD19 CAR T Cells in Blood

Time frame: Day 7, Week 2, Week 4, Month 3, Month 6, Month 12, Month 18 and Month 24

Population: Participants in the Safety Analysis Set with available data were analyzed.

Arm	Measure	Group	Value (MEAN)	Dispersion
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Anti-CD19 CAR T Cells in Blood	Day 7	101.49 cells/μL	Standard Deviation 220.01
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Anti-CD19 CAR T Cells in Blood	Week 2	41.45 cells/μL	Standard Deviation 63.65
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Anti-CD19 CAR T Cells in Blood	Week 4	7.52 cells/μL	Standard Deviation 19.85
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Anti-CD19 CAR T Cells in Blood	Month 3	0.78 cells/μL	Standard Deviation 1.91
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Anti-CD19 CAR T Cells in Blood	Month 6	3.49 cells/μL	Standard Deviation 28.89
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Anti-CD19 CAR T Cells in Blood	Month 12	1.00 cells/μL	Standard Deviation 5.65
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Anti-CD19 CAR T Cells in Blood	Month 18	0.47 cells/μL	Standard Deviation 1.51
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Anti-CD19 CAR T Cells in Blood	Month 24	0.36 cells/μL	Standard Deviation 0.84
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Anti-CD19 CAR T Cells in Blood	Month 24	0.88 cells/μL	Standard Deviation 2.09
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Anti-CD19 CAR T Cells in Blood	Day 7	120.07 cells/μL	Standard Deviation 394.91
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Anti-CD19 CAR T Cells in Blood	Month 6	0.68 cells/μL	Standard Deviation 1.9
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Anti-CD19 CAR T Cells in Blood	Week 2	90.76 cells/μL	Standard Deviation 128.63
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Anti-CD19 CAR T Cells in Blood	Month 18	0.42 cells/μL	Standard Deviation 0.77
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Anti-CD19 CAR T Cells in Blood	Week 4	14.03 cells/μL	Standard Deviation 23.43
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Anti-CD19 CAR T Cells in Blood	Month 12	0.23 cells/μL	Standard Deviation 0.43
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Anti-CD19 CAR T Cells in Blood	Month 3	0.52 cells/μL	Standard Deviation 0.51

Secondary

Levels of Serum C-Reactive Protein (CRP)

Time frame: Baseline (at enrollment), predose: Day 0, postdose: Day 3, Day 7, Week 2, Week 4

Population: Participants in the Safety Analysis Set with available data were analyzed.

Arm	Measure	Group	Value (MEAN)	Dispersion
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum C-Reactive Protein (CRP)	Serum CRP on Day 3	72.50 mg/L	Standard Deviation 91.76
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum C-Reactive Protein (CRP)	Serum CRP on Week 2	9.07 mg/L	Standard Deviation 19.7
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum C-Reactive Protein (CRP)	Serum CRP on Day 0	29.30 mg/L	Standard Deviation 47.35
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum C-Reactive Protein (CRP)	Serum CRP on Week 4	7.84 mg/L	Standard Deviation 33.76
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum C-Reactive Protein (CRP)	Serum CRP on Day 7	59.45 mg/L	Standard Deviation 79.24
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum C-Reactive Protein (CRP)	Serum CRP on Baseline	22.36 mg/L	Standard Deviation 40.6
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum C-Reactive Protein (CRP)	Serum CRP on Day 0	32.94 mg/L	Standard Deviation 42.5
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum C-Reactive Protein (CRP)	Serum CRP on Baseline	19.87 mg/L	Standard Deviation 28.62
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum C-Reactive Protein (CRP)	Serum CRP on Day 3	66.73 mg/L	Standard Deviation 92.82
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum C-Reactive Protein (CRP)	Serum CRP on Day 7	77.79 mg/L	Standard Deviation 91.86
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum C-Reactive Protein (CRP)	Serum CRP on Week 2	13.59 mg/L	Standard Deviation 42.2
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum C-Reactive Protein (CRP)	Serum CRP on Week 4	9.86 mg/L	Standard Deviation 43.46

Secondary

Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha

Serum analytes: Serum CXCL10, Serum Granzyme B, Serum interferon (IFN)-gamma, Serum IL-1 receptor antagonist (RA), Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum tumor necrosis factor (TNF) Alpha.

Time frame: Baseline (at enrollment), predose: Day 0, postdose: Day 3, Day 7, Week 2, Week 4

Population: Participants in the Safety Analysis Set with available data were analyzed.

Arm	Measure	Group	Value (MEAN)	Dispersion
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-1 RA on Day 3	703.79 pg/mL	Standard Deviation 772.95
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-8 on Baseline	13.59 pg/mL	Standard Deviation 15.09
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum Granzyme B on Week 4	3.14 pg/mL	Standard Deviation 5.15
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-8 on Day 0	21.12 pg/mL	Standard Deviation 33.53
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-1 RA on Day 7	1125.80 pg/mL	Standard Deviation 1316.88
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-8 on Week 4	20.36 pg/mL	Standard Deviation 68.72
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum CXCL10 on Week 4	623.87 pg/mL	Standard Deviation 535.45
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-10 on Baseline	2.85 pg/mL	Standard Deviation 3.76
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-1 RA on Week 2	591.72 pg/mL	Standard Deviation 764.19
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-10 on Day 0	1.93 pg/mL	Standard Deviation 2.29
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IFN-gamma on Baseline	9.25 pg/mL	Standard Deviation 7.17
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-10 on Day 3	9.34 pg/mL	Standard Deviation 17.6
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-2 on Day 3	8.01 pg/mL	Standard Deviation 13.08
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-10 on Day 7	15.01 pg/mL	Standard Deviation 34.55
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum CXCL10 on Day 7	841.62 pg/mL	Standard Deviation 572.8
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-10 on Week 2	2.06 pg/mL	Standard Deviation 4.64
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum CXCL10 on Baseline	466.32 pg/mL	Standard Deviation 339
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-10 on Week 4	1.10 pg/mL	Standard Deviation 1.31
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-2 on Day 7	1.67 pg/mL	Standard Deviation 2.55
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-15 on Baseline	2.70 pg/mL	Standard Deviation 2.69
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IFN-gamma on Day 0	11.20 pg/mL	Standard Deviation 16.17
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-15 on Day 0	31.06 pg/mL	Standard Deviation 13.55
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-2 on Week 2	0.95 pg/mL	Standard Deviation 0.48
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-15 on Week 4	4.98 pg/mL	Standard Deviation 3.52
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum Granzyme B on Baseline	3.58 pg/mL	Standard Deviation 9.68
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum TNF Alpha on Baseline	7.26 pg/mL	Standard Deviation 7.87
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-2 on Week 4	0.95 pg/mL	Standard Deviation 0.5
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum TNF Alpha on Day 0	3.32 pg/mL	Standard Deviation 2.62
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IFN-gamma on Day 3	157.13 pg/mL	Standard Deviation 326.44
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum TNF Alpha on Day 3	3.95 pg/mL	Standard Deviation 2.68
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-6 on Baseline	2.71 pg/mL	Standard Deviation 2.9
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum TNF Alpha on Week 2	2.84 pg/mL	Standard Deviation 6.01
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum CXCL10 on Day 3	712.31 pg/mL	Standard Deviation 543.76
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum TNF Alpha on Week 4	2.36 pg/mL	Standard Deviation 1.65
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-6 on Day 0	2.42 pg/mL	Standard Deviation 2.27
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IFN-gamma on Day 7	139.82 pg/mL	Standard Deviation 359.84
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-6 on Day 3	59.30 pg/mL	Standard Deviation 185.89
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum Granzyme B on Day 7	76.29 pg/mL	Standard Deviation 494.66
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum Granzyme B on Week 2	2.73 pg/mL	Standard Deviation 5.67
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum Granzyme B on Day 0	2.95 pg/mL	Standard Deviation 7.86
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-1 RA on Day 0	677.50 pg/mL	Standard Deviation 743.22
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-6 on Week 2	20.01 pg/mL	Standard Deviation 92.15
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IFN-gamma on Week 2	25.98 pg/mL	Standard Deviation 48.82
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-1 RA on Week 4	653.88 pg/mL	Standard Deviation 1197.23
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-6 on Week 4	31.02 pg/mL	Standard Deviation 122.14
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-2 on Baseline	1.03 pg/mL	Standard Deviation 0.53
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-2 on Day 0	1.20 pg/mL	Standard Deviation 1.22
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum CXCL10 on Week 2	474.45 pg/mL	Standard Deviation 371.95
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-6 on Day 7	67.49 pg/mL	Standard Deviation 197.95
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-7 on Baseline	15.99 pg/mL	Standard Deviation 7.89
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IFN-gamma on Week 4	23.96 pg/mL	Standard Deviation 37.04
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-7 on Week 2	27.25 pg/mL	Standard Deviation 14.13
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-7 on Day 0	27.65 pg/mL	Standard Deviation 9.62
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-8 on Day 3	60.27 pg/mL	Standard Deviation 126.84
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum Granzyme B on Day 3	6.53 pg/mL	Standard Deviation 11.03
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-8 on Day 7	45.79 pg/mL	Standard Deviation 86.38
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-8 on Week 2	16.08 pg/mL	Standard Deviation 17.14
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-7 on Day 3	26.50 pg/mL	Standard Deviation 10.22
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-15 on Day 3	35.27 pg/mL	Standard Deviation 19.66
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-1 RA on Baseline	584.66 pg/mL	Standard Deviation 400.47
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-15 on Day 7	18.73 pg/mL	Standard Deviation 9.77
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-7 on Day 7	23.42 pg/mL	Standard Deviation 11.28
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-15 on Week 2	10.30 pg/mL	Standard Deviation 5.9
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum CXCL10 on Day 0	499.16 pg/mL	Standard Deviation 334.85
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-7 on Week 4	18.45 pg/mL	Standard Deviation 8.92
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum TNF Alpha on Day 7	3.93 pg/mL	Standard Deviation 3.1
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-10 on Week 2	3.42 pg/mL	Standard Deviation 4.88
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum CXCL10 on Baseline	634.56 pg/mL	Standard Deviation 539.17
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum CXCL10 on Day 3	962.96 pg/mL	Standard Deviation 611.23
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum CXCL10 on Day 7	1630.98 pg/mL	Standard Deviation 563.4
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum CXCL10 on Week 2	798.28 pg/mL	Standard Deviation 631.8
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum CXCL10 on Week 4	964.92 pg/mL	Standard Deviation 640.57
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum Granzyme B on Baseline	121.49 pg/mL	Standard Deviation 623.76
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum Granzyme B on Day 0	46.36 pg/mL	Standard Deviation 234.23
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum Granzyme B on Day 7	52.87 pg/mL	Standard Deviation 68.63
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum Granzyme B on Week 4	17.00 pg/mL	Standard Deviation 39.9
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IFN-gamma on Baseline	30.29 pg/mL	Standard Deviation 83.67
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IFN-gamma on Day 0	54.04 pg/mL	Standard Deviation 140.4
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IFN-gamma on Day 3	292.67 pg/mL	Standard Deviation 531.54
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IFN-gamma on Day 7	674.34 pg/mL	Standard Deviation 792.31
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IFN-gamma on Week 2	27.16 pg/mL	Standard Deviation 37.43
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IFN-gamma on Week 4	56.72 pg/mL	Standard Deviation 108.1
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-1 RA on Baseline	627.95 pg/mL	Standard Deviation 467.39
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-1 RA on Day 3	848.20 pg/mL	Standard Deviation 757.98
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-1 RA on Day 7	2492.85 pg/mL	Standard Deviation 2895.93
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-2 on Baseline	1.12 pg/mL	Standard Deviation 0.9
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-2 on Day 3	12.43 pg/mL	Standard Deviation 34.49
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-2 on Day 7	2.99 pg/mL	Standard Deviation 3.78
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-2 on Week 2	0.93 pg/mL	Standard Deviation 0.18
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-2 on Week 4	1.10 pg/mL	Standard Deviation 1.06
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-6 on Baseline	5.08 pg/mL	Standard Deviation 8.11
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-6 on Day 0	4.14 pg/mL	Standard Deviation 5.39
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-6 on Day 3	103.93 pg/mL	Standard Deviation 281.61
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-6 on Week 2	33.00 pg/mL	Standard Deviation 66.24
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-6 on Week 4	58.84 pg/mL	Standard Deviation 169.85
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-7 on Baseline	15.30 pg/mL	Standard Deviation 7.13
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-7 on Day 0	28.31 pg/mL	Standard Deviation 10.15
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-7 on Day 3	27.24 pg/mL	Standard Deviation 10.82
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-7 on Week 2	26.38 pg/mL	Standard Deviation 16.52
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-7 on Week 4	20.30 pg/mL	Standard Deviation 10.52
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-8 on Baseline	13.71 pg/mL	Standard Deviation 9.11
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-8 on Day 7	37.47 pg/mL	Standard Deviation 30.74
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-8 on Week 4	18.90 pg/mL	Standard Deviation 13.8
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-10 on Baseline	5.11 pg/mL	Standard Deviation 6.72
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-10 on Day 0	1.89 pg/mL	Standard Deviation 2.18
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-10 on Day 3	7.39 pg/mL	Standard Deviation 10.14
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-10 on Day 7	20.32 pg/mL	Standard Deviation 20.7
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-10 on Week 4	1.65 pg/mL	Standard Deviation 2.08
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-15 on Baseline	2.59 pg/mL	Standard Deviation 1.42
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-15 on Day 0	33.89 pg/mL	Standard Deviation 16.32
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-15 on Week 4	7.41 pg/mL	Standard Deviation 5.21
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum TNF Alpha on Baseline	6.73 pg/mL	Standard Deviation 7.86
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum TNF Alpha on Day 0	3.08 pg/mL	Standard Deviation 1.68
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum TNF Alpha on Day 7	5.97 pg/mL	Standard Deviation 4.09
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum TNF Alpha on Week 2	2.74 pg/mL	Standard Deviation 2.3
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum TNF Alpha on Week 4	3.03 pg/mL	Standard Deviation 2.13
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum CXCL10 on Day 0	763.99 pg/mL	Standard Deviation 569.42
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum Granzyme B on Day 3	74.28 pg/mL	Standard Deviation 348.53
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum Granzyme B on Week 2	27.21 pg/mL	Standard Deviation 102.65
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-1 RA on Day 0	960.41 pg/mL	Standard Deviation 1342.3
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-1 RA on Week 2	854.68 pg/mL	Standard Deviation 1693.69
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-1 RA on Week 4	1106.94 pg/mL	Standard Deviation 1935.55
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-2 on Day 0	1.16 pg/mL	Standard Deviation 1.09
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-6 on Day 7	206.75 pg/mL	Standard Deviation 282.31
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-7 on Day 7	23.28 pg/mL	Standard Deviation 11.69
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-8 on Day 0	42.71 pg/mL	Standard Deviation 129.39
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-8 on Day 3	80.86 pg/mL	Standard Deviation 154.41
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-8 on Week 2	41.41 pg/mL	Standard Deviation 117.98
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-15 on Day 3	43.43 pg/mL	Standard Deviation 37.4
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-15 on Day 7	25.22 pg/mL	Standard Deviation 15.38
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum IL-15 on Week 2	12.92 pg/mL	Standard Deviation 8.28
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha	Serum TNF Alpha on Day 3	4.90 pg/mL	Standard Deviation 4.59

Secondary

Levels of Serum Ferritin, Serum ICAM-1, Serum IL-2 R Alpha, Serum Perforin and Serum VCAM-1

Serum analytes: Serum Ferritin, Serum intercellular adhesion molecule-1 (ICAM-1), Serum interleukin-2 receptor (IL-2 R) alpha, Serum Perforin and Serum vascular cell adhesion molecule-1 (VCAM-1).

Time frame: Baseline (at enrollment), predose: Day 0, postdose: Day 3, Day 7, Week 2, Week 4

Population: Participants in the Safety Analysis Set with available data were analyzed.

Arm	Measure	Group	Value (MEAN)	Dispersion
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum Ferritin, Serum ICAM-1, Serum IL-2 R Alpha, Serum Perforin and Serum VCAM-1	Serum Perforin on Week 4	14.56 ng/L	Standard Deviation 11.92
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum Ferritin, Serum ICAM-1, Serum IL-2 R Alpha, Serum Perforin and Serum VCAM-1	Serum Ferritin on Day 0	503.99 ng/L	Standard Deviation 502.07
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum Ferritin, Serum ICAM-1, Serum IL-2 R Alpha, Serum Perforin and Serum VCAM-1	Serum Ferritin on Day 3	541.51 ng/L	Standard Deviation 457.18
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum Ferritin, Serum ICAM-1, Serum IL-2 R Alpha, Serum Perforin and Serum VCAM-1	Serum Ferritin on Day 7	779.75 ng/L	Standard Deviation 782.98
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum Ferritin, Serum ICAM-1, Serum IL-2 R Alpha, Serum Perforin and Serum VCAM-1	Serum Ferritin on Week 2	741.76 ng/L	Standard Deviation 787.7
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum Ferritin, Serum ICAM-1, Serum IL-2 R Alpha, Serum Perforin and Serum VCAM-1	Serum Ferritin on Week 4	528.83 ng/L	Standard Deviation 605.94
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum Ferritin, Serum ICAM-1, Serum IL-2 R Alpha, Serum Perforin and Serum VCAM-1	Serum ICAM-1 on Baseline	876.99 ng/L	Standard Deviation 833.8
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum Ferritin, Serum ICAM-1, Serum IL-2 R Alpha, Serum Perforin and Serum VCAM-1	Serum ICAM-1 on Day 0	834.87 ng/L	Standard Deviation 854.35
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum Ferritin, Serum ICAM-1, Serum IL-2 R Alpha, Serum Perforin and Serum VCAM-1	Serum ICAM-1 on Day 3	964.45 ng/L	Standard Deviation 904.79
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum Ferritin, Serum ICAM-1, Serum IL-2 R Alpha, Serum Perforin and Serum VCAM-1	Serum ICAM-1 on Day 7	924.99 ng/L	Standard Deviation 846.56
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum Ferritin, Serum ICAM-1, Serum IL-2 R Alpha, Serum Perforin and Serum VCAM-1	Serum ICAM-1 on Week 2	695.15 ng/L	Standard Deviation 605.03
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum Ferritin, Serum ICAM-1, Serum IL-2 R Alpha, Serum Perforin and Serum VCAM-1	Serum ICAM-1 on Week 4	671.32 ng/L	Standard Deviation 656.46
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum Ferritin, Serum ICAM-1, Serum IL-2 R Alpha, Serum Perforin and Serum VCAM-1	Serum IL-2 R alpha on Baseline	8.52 ng/L	Standard Deviation 12.15
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum Ferritin, Serum ICAM-1, Serum IL-2 R Alpha, Serum Perforin and Serum VCAM-1	Serum IL-2 R alpha on Day 0	8.39 ng/L	Standard Deviation 9.1
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum Ferritin, Serum ICAM-1, Serum IL-2 R Alpha, Serum Perforin and Serum VCAM-1	Serum IL-2 R alpha on Day 3	9.96 ng/L	Standard Deviation 11.53
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum Ferritin, Serum ICAM-1, Serum IL-2 R Alpha, Serum Perforin and Serum VCAM-1	Serum IL-2 R alpha on Day 7	14.42 ng/L	Standard Deviation 15.1
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum Ferritin, Serum ICAM-1, Serum IL-2 R Alpha, Serum Perforin and Serum VCAM-1	Serum IL-2 R alpha on Week 2	7.16 ng/L	Standard Deviation 8.27
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum Ferritin, Serum ICAM-1, Serum IL-2 R Alpha, Serum Perforin and Serum VCAM-1	Serum IL-2 R alpha on Week 4	3.39 ng/L	Standard Deviation 3.34
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum Ferritin, Serum ICAM-1, Serum IL-2 R Alpha, Serum Perforin and Serum VCAM-1	Serum Perforin on Day 0	2.56 ng/L	Standard Deviation 1.85
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum Ferritin, Serum ICAM-1, Serum IL-2 R Alpha, Serum Perforin and Serum VCAM-1	Serum Perforin on Day 3	3.87 ng/L	Standard Deviation 3.36
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum Ferritin, Serum ICAM-1, Serum IL-2 R Alpha, Serum Perforin and Serum VCAM-1	Serum Perforin on Day 7	8.49 ng/L	Standard Deviation 10.54
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum Ferritin, Serum ICAM-1, Serum IL-2 R Alpha, Serum Perforin and Serum VCAM-1	Serum Perforin on Week 2	8.06 ng/L	Standard Deviation 6.9
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum Ferritin, Serum ICAM-1, Serum IL-2 R Alpha, Serum Perforin and Serum VCAM-1	Serum Ferritin on Baseline	330.54 ng/L	Standard Deviation 398.03
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum Ferritin, Serum ICAM-1, Serum IL-2 R Alpha, Serum Perforin and Serum VCAM-1	Serum VCAM-1 on Baseline	1499.37 ng/L	Standard Deviation 1637.98
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum Ferritin, Serum ICAM-1, Serum IL-2 R Alpha, Serum Perforin and Serum VCAM-1	Serum VCAM-1 on Day 0	1182.41 ng/L	Standard Deviation 1166.58
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum Ferritin, Serum ICAM-1, Serum IL-2 R Alpha, Serum Perforin and Serum VCAM-1	Serum VCAM-1 on Day 3	1213.84 ng/L	Standard Deviation 962.38
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum Ferritin, Serum ICAM-1, Serum IL-2 R Alpha, Serum Perforin and Serum VCAM-1	Serum VCAM-1 on Day 7	1224.58 ng/L	Standard Deviation 1069.13
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum Ferritin, Serum ICAM-1, Serum IL-2 R Alpha, Serum Perforin and Serum VCAM-1	Serum VCAM-1 on Week 2	891.64 ng/L	Standard Deviation 726.1
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum Ferritin, Serum ICAM-1, Serum IL-2 R Alpha, Serum Perforin and Serum VCAM-1	Serum VCAM-1 on Week 4	981.67 ng/L	Standard Deviation 879.87
Axicabtagene Ciloleucel (Follicular Lymphoma)	Levels of Serum Ferritin, Serum ICAM-1, Serum IL-2 R Alpha, Serum Perforin and Serum VCAM-1	Serum Perforin on Baseline	13.26 ng/L	Standard Deviation 7.2
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum Ferritin, Serum ICAM-1, Serum IL-2 R Alpha, Serum Perforin and Serum VCAM-1	Serum VCAM-1 on Day 3	1044.96 ng/L	Standard Deviation 870.11
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum Ferritin, Serum ICAM-1, Serum IL-2 R Alpha, Serum Perforin and Serum VCAM-1	Serum Ferritin on Baseline	207.63 ng/L	Standard Deviation 218.42
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum Ferritin, Serum ICAM-1, Serum IL-2 R Alpha, Serum Perforin and Serum VCAM-1	Serum IL-2 R alpha on Day 7	19.78 ng/L	Standard Deviation 20.82
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum Ferritin, Serum ICAM-1, Serum IL-2 R Alpha, Serum Perforin and Serum VCAM-1	Serum Ferritin on Day 0	398.49 ng/L	Standard Deviation 337.82
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum Ferritin, Serum ICAM-1, Serum IL-2 R Alpha, Serum Perforin and Serum VCAM-1	Serum Perforin on Week 4	12.32 ng/L	Standard Deviation 12.08
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum Ferritin, Serum ICAM-1, Serum IL-2 R Alpha, Serum Perforin and Serum VCAM-1	Serum Ferritin on Day 3	487.39 ng/L	Standard Deviation 414.9
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum Ferritin, Serum ICAM-1, Serum IL-2 R Alpha, Serum Perforin and Serum VCAM-1	Serum IL-2 R alpha on Week 2	10.40 ng/L	Standard Deviation 12.26
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum Ferritin, Serum ICAM-1, Serum IL-2 R Alpha, Serum Perforin and Serum VCAM-1	Serum Ferritin on Day 7	1820.38 ng/L	Standard Deviation 4837.56
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum Ferritin, Serum ICAM-1, Serum IL-2 R Alpha, Serum Perforin and Serum VCAM-1	Serum VCAM-1 on Week 2	977.88 ng/L	Standard Deviation 919.47
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum Ferritin, Serum ICAM-1, Serum IL-2 R Alpha, Serum Perforin and Serum VCAM-1	Serum Ferritin on Week 2	959.49 ng/L	Standard Deviation 1546.07
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum Ferritin, Serum ICAM-1, Serum IL-2 R Alpha, Serum Perforin and Serum VCAM-1	Serum IL-2 R alpha on Week 4	4.02 ng/L	Standard Deviation 3.67
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum Ferritin, Serum ICAM-1, Serum IL-2 R Alpha, Serum Perforin and Serum VCAM-1	Serum Ferritin on Week 4	478.47 ng/L	Standard Deviation 459.54
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum Ferritin, Serum ICAM-1, Serum IL-2 R Alpha, Serum Perforin and Serum VCAM-1	Serum Perforin on Baseline	13.58 ng/L	Standard Deviation 18.33
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum Ferritin, Serum ICAM-1, Serum IL-2 R Alpha, Serum Perforin and Serum VCAM-1	Serum ICAM-1 on Baseline	709.71 ng/L	Standard Deviation 430.14
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum Ferritin, Serum ICAM-1, Serum IL-2 R Alpha, Serum Perforin and Serum VCAM-1	Serum VCAM-1 on Baseline	1282.81 ng/L	Standard Deviation 1232.76
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum Ferritin, Serum ICAM-1, Serum IL-2 R Alpha, Serum Perforin and Serum VCAM-1	Serum ICAM-1 on Day 0	642.60 ng/L	Standard Deviation 365.92
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum Ferritin, Serum ICAM-1, Serum IL-2 R Alpha, Serum Perforin and Serum VCAM-1	Serum Perforin on Day 0	3.30 ng/L	Standard Deviation 9.11
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum Ferritin, Serum ICAM-1, Serum IL-2 R Alpha, Serum Perforin and Serum VCAM-1	Serum ICAM-1 on Day 3	792.47 ng/L	Standard Deviation 621.84
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum Ferritin, Serum ICAM-1, Serum IL-2 R Alpha, Serum Perforin and Serum VCAM-1	Serum VCAM-1 on Day 7	1209.51 ng/L	Standard Deviation 780.31
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum Ferritin, Serum ICAM-1, Serum IL-2 R Alpha, Serum Perforin and Serum VCAM-1	Serum ICAM-1 on Day 7	934.02 ng/L	Standard Deviation 618.96
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum Ferritin, Serum ICAM-1, Serum IL-2 R Alpha, Serum Perforin and Serum VCAM-1	Serum Perforin on Day 3	4.71 ng/L	Standard Deviation 13.53
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum Ferritin, Serum ICAM-1, Serum IL-2 R Alpha, Serum Perforin and Serum VCAM-1	Serum ICAM-1 on Week 2	696.77 ng/L	Standard Deviation 438.71
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum Ferritin, Serum ICAM-1, Serum IL-2 R Alpha, Serum Perforin and Serum VCAM-1	Serum VCAM-1 on Day 0	931.58 ng/L	Standard Deviation 709.94
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum Ferritin, Serum ICAM-1, Serum IL-2 R Alpha, Serum Perforin and Serum VCAM-1	Serum ICAM-1 on Week 4	614.92 ng/L	Standard Deviation 487.67
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum Ferritin, Serum ICAM-1, Serum IL-2 R Alpha, Serum Perforin and Serum VCAM-1	Serum Perforin on Day 7	6.60 ng/L	Standard Deviation 7.99
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum Ferritin, Serum ICAM-1, Serum IL-2 R Alpha, Serum Perforin and Serum VCAM-1	Serum IL-2 R alpha on Baseline	5.62 ng/L	Standard Deviation 7.5
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum Ferritin, Serum ICAM-1, Serum IL-2 R Alpha, Serum Perforin and Serum VCAM-1	Serum VCAM-1 on Week 4	930.89 ng/L	Standard Deviation 885.51
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum Ferritin, Serum ICAM-1, Serum IL-2 R Alpha, Serum Perforin and Serum VCAM-1	Serum IL-2 R alpha on Day 0	4.91 ng/L	Standard Deviation 4.12
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum Ferritin, Serum ICAM-1, Serum IL-2 R Alpha, Serum Perforin and Serum VCAM-1	Serum Perforin on Week 2	6.01 ng/L	Standard Deviation 6.77
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Levels of Serum Ferritin, Serum ICAM-1, Serum IL-2 R Alpha, Serum Perforin and Serum VCAM-1	Serum IL-2 R alpha on Day 3	7.31 ng/L	Standard Deviation 5.68

Secondary

ORR: Percentage of Participants With OR Per the Lugano Classification by Central Assessment Among Participants With 3 or More Lines of Prior Therapy

OR was defined as percentage of participants with CR + PR per the Lugano Classification for participants with 3 or more lines of prior therapy. CR and PR are defined in OM#1. Percentages were rounded-off.

Time frame: Up to 85.6 months

Population: Participants with 3 or more lines of prior therapy in the Full Analysis Set with available data were analyzed

Arm	Measure	Value (NUMBER)
Axicabtagene Ciloleucel (Follicular Lymphoma)	ORR: Percentage of Participants With OR Per the Lugano Classification by Central Assessment Among Participants With 3 or More Lines of Prior Therapy	91 percentage of participants
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	ORR: Percentage of Participants With OR Per the Lugano Classification by Central Assessment Among Participants With 3 or More Lines of Prior Therapy	75 percentage of participants

Secondary

ORR: Percentage of Participants With OR Per the Lugano Classification by Investigator Assessment

OR was defined as percentage of participants with CR + PR per the Lugano Classification. CR and PR are defined in OM#1. Percentages were rounded-off.

Time frame: Up to 85.6 months

Population: Participants in the Full Analysis Set were analyzed.

Arm	Measure	Value (NUMBER)
Axicabtagene Ciloleucel (Follicular Lymphoma)	ORR: Percentage of Participants With OR Per the Lugano Classification by Investigator Assessment	94 percentage of participants
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	ORR: Percentage of Participants With OR Per the Lugano Classification by Investigator Assessment	77 percentage of participants

Secondary

Overall Survival (OS)

OS was defined as the time from axicabtagene ciloleucel infusion to the date of death. KM estimates were used for analysis.

Time frame: Up to 85.6

Population: Participants in the Full Analysis Set were analyzed.

Arm	Measure	Value (MEDIAN)
Axicabtagene Ciloleucel (Follicular Lymphoma)	Overall Survival (OS)	NA months
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Overall Survival (OS)	NA months

Secondary

Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)

TEAE was defined as any adverse event with onset on or after the start of treatment. Percentages were rounded-off.

Time frame: Up to 85.6 months

Population: Participants in the Safety Analysis Set were analyzed.

Arm	Measure	Value (NUMBER)
Axicabtagene Ciloleucel (Follicular Lymphoma)	Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)	99 percentage of participants
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)	100 percentage of participants

Secondary

Percentage of Participants With Antibodies Against Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells

Time frame: Up to 85.6 months

Population: Participants from the Safety Analysis Set were analyzed.

Arm	Measure	Value (NUMBER)
Axicabtagene Ciloleucel (Follicular Lymphoma)	Percentage of Participants With Antibodies Against Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells	0 percentage of participants
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Percentage of Participants With Antibodies Against Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells	0 percentage of participants

Secondary

Percentage of Participants With Best Overall Response (BOR) Per the Lugano Classification by Central Assessment

BOR was defined as percentage of participants with CR, PR, stable disease(SD), disease progression(PD), non-evaluable(NE), undefined/no disease or not done as best response to treatment by the Lugano Classification. CR and PR defined in OM#1. SD/no metabolic response(NMR):score 4(uptake moderately greater than (\>) liver) or 5(uptake markedly\>liver and/ or new lesions) with no significant change in fluorodeoxyglucose(FDG) uptake compared to baseline(screening), at interim time point or end of treatment; no new sites of disease should be observed. PD:score 4(uptake moderately\>liver) or 5(uptake markedly\>liver and/or new lesions) with an increase in intensity of uptake from baseline; new FDG-avid foci consistent with lymphoma at interim or end of treatment assessment; new FDG-avid foci consistent with lymphoma rather than another etiology (eg, infection, inflammation); new or recurrent FDG-avid foci in bone marrow. Not done:no assessment at time of analysis. Percentages were rounded off.

Time frame: Up to 85.6 months

Population: Participants in the Full Analysis Set with available data were analyzed

Arm	Measure	Group	Value (NUMBER)
Axicabtagene Ciloleucel (Follicular Lymphoma)	Percentage of Participants With Best Overall Response (BOR) Per the Lugano Classification by Central Assessment	SD	4 percentage of participants
Axicabtagene Ciloleucel (Follicular Lymphoma)	Percentage of Participants With Best Overall Response (BOR) Per the Lugano Classification by Central Assessment	Non-evaluable	0 percentage of participants
Axicabtagene Ciloleucel (Follicular Lymphoma)	Percentage of Participants With Best Overall Response (BOR) Per the Lugano Classification by Central Assessment	PR	14 percentage of participants
Axicabtagene Ciloleucel (Follicular Lymphoma)	Percentage of Participants With Best Overall Response (BOR) Per the Lugano Classification by Central Assessment	Undefined/ No Disease	1 percentage of participants
Axicabtagene Ciloleucel (Follicular Lymphoma)	Percentage of Participants With Best Overall Response (BOR) Per the Lugano Classification by Central Assessment	PD	0 percentage of participants
Axicabtagene Ciloleucel (Follicular Lymphoma)	Percentage of Participants With Best Overall Response (BOR) Per the Lugano Classification by Central Assessment	Not Done	3 percentage of participants
Axicabtagene Ciloleucel (Follicular Lymphoma)	Percentage of Participants With Best Overall Response (BOR) Per the Lugano Classification by Central Assessment	CR	78 percentage of participants
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Percentage of Participants With Best Overall Response (BOR) Per the Lugano Classification by Central Assessment	Not Done	17 percentage of participants
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Percentage of Participants With Best Overall Response (BOR) Per the Lugano Classification by Central Assessment	CR	52 percentage of participants
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Percentage of Participants With Best Overall Response (BOR) Per the Lugano Classification by Central Assessment	PR	17 percentage of participants
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Percentage of Participants With Best Overall Response (BOR) Per the Lugano Classification by Central Assessment	SD	0 percentage of participants
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Percentage of Participants With Best Overall Response (BOR) Per the Lugano Classification by Central Assessment	PD	3 percentage of participants
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Percentage of Participants With Best Overall Response (BOR) Per the Lugano Classification by Central Assessment	Non-evaluable	0 percentage of participants
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Percentage of Participants With Best Overall Response (BOR) Per the Lugano Classification by Central Assessment	Undefined/ No Disease	10 percentage of participants

Secondary

Percentage of Participants With BOR Per the Lugano Classification by Investigator Assessment

BOR was defined as the percentage of participants with CR, PR, stable disease (SD), PD, NE (not evaluable) or not done as best response to treatment by the Lugano Classification. CR and PR are defined in OM#1. SD, PD and not done are defined in OM#6. Percentages were rounded off.

Time frame: Up to 85.6 months

Population: Participants in the Full Analysis Set were analyzed.

Arm	Measure	Group	Value (NUMBER)
Axicabtagene Ciloleucel (Follicular Lymphoma)	Percentage of Participants With BOR Per the Lugano Classification by Investigator Assessment	PD	2 percentage of participants
Axicabtagene Ciloleucel (Follicular Lymphoma)	Percentage of Participants With BOR Per the Lugano Classification by Investigator Assessment	PR	15 percentage of participants
Axicabtagene Ciloleucel (Follicular Lymphoma)	Percentage of Participants With BOR Per the Lugano Classification by Investigator Assessment	NE	0 percentage of participants
Axicabtagene Ciloleucel (Follicular Lymphoma)	Percentage of Participants With BOR Per the Lugano Classification by Investigator Assessment	SD	2 percentage of participants
Axicabtagene Ciloleucel (Follicular Lymphoma)	Percentage of Participants With BOR Per the Lugano Classification by Investigator Assessment	Not Done	3 percentage of participants
Axicabtagene Ciloleucel (Follicular Lymphoma)	Percentage of Participants With BOR Per the Lugano Classification by Investigator Assessment	CR	79 percentage of participants
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Percentage of Participants With BOR Per the Lugano Classification by Investigator Assessment	Not Done	10 percentage of participants
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Percentage of Participants With BOR Per the Lugano Classification by Investigator Assessment	PR	13 percentage of participants
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Percentage of Participants With BOR Per the Lugano Classification by Investigator Assessment	SD	10 percentage of participants
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Percentage of Participants With BOR Per the Lugano Classification by Investigator Assessment	PD	3 percentage of participants
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Percentage of Participants With BOR Per the Lugano Classification by Investigator Assessment	NE	0 percentage of participants
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Percentage of Participants With BOR Per the Lugano Classification by Investigator Assessment	CR	65 percentage of participants

Secondary

Percentage of Participants With CR Per Lugano Classification by Central Assessment Among Participants With 3 or More Lines of Prior Therapy

CR is defined as OM#1. Percentages were rounded-off.

Time frame: Up to 85.6 months

Population: Participants with 3 or more lines of prior therapy in the Full Analysis Set with available data were analyzed

Arm	Measure	Value (NUMBER)
Axicabtagene Ciloleucel (Follicular Lymphoma)	Percentage of Participants With CR Per Lugano Classification by Central Assessment Among Participants With 3 or More Lines of Prior Therapy	79 percentage of participants
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Percentage of Participants With CR Per Lugano Classification by Central Assessment Among Participants With 3 or More Lines of Prior Therapy	60 percentage of participants

Secondary

Percentage of Participants With CR Per the Lugano Classification by Central Assessment

CR is defined in outcome measure (OM)#1. Percentages were rounded-off.

Time frame: Up to 85.6 months

Population: Participants in the Full Analysis Set with available data were analyzed.

Arm	Measure	Value (NUMBER)
Axicabtagene Ciloleucel (Follicular Lymphoma)	Percentage of Participants With CR Per the Lugano Classification by Central Assessment	78 percentage of participants
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Percentage of Participants With CR Per the Lugano Classification by Central Assessment	52 percentage of participants

Secondary

Percentage of Participants With Decrease in Laboratory Values Reported as Grade 3 or Higher

Percentages were rounded-off.

Time frame: Up to 85.6 months

Population: Participants in the Safety Analysis Set were analyzed.

Arm	Measure	Group	Value (NUMBER)
Axicabtagene Ciloleucel (Follicular Lymphoma)	Percentage of Participants With Decrease in Laboratory Values Reported as Grade 3 or Higher	Grade 3 or Higher Decrease in Platelets (10^9/L)	35 percentage of participants
Axicabtagene Ciloleucel (Follicular Lymphoma)	Percentage of Participants With Decrease in Laboratory Values Reported as Grade 3 or Higher	Grade 3 or Higher Decrease in Phosphate (mmol/L)	23 percentage of participants
Axicabtagene Ciloleucel (Follicular Lymphoma)	Percentage of Participants With Decrease in Laboratory Values Reported as Grade 3 or Higher	Grade 3 or Higher Decrease in Calcium (mmol/L)	10 percentage of participants
Axicabtagene Ciloleucel (Follicular Lymphoma)	Percentage of Participants With Decrease in Laboratory Values Reported as Grade 3 or Higher	Grade 3 or Higher Decrease in Potassium (mmol/L)	4 percentage of participants
Axicabtagene Ciloleucel (Follicular Lymphoma)	Percentage of Participants With Decrease in Laboratory Values Reported as Grade 3 or Higher	Grade 3 or Higher Decrease in Neutrophils (10^9/L)	92 percentage of participants
Axicabtagene Ciloleucel (Follicular Lymphoma)	Percentage of Participants With Decrease in Laboratory Values Reported as Grade 3 or Higher	Grade 3 or Higher Decrease in Sodium (mmol/L)	9 percentage of participants
Axicabtagene Ciloleucel (Follicular Lymphoma)	Percentage of Participants With Decrease in Laboratory Values Reported as Grade 3 or Higher	Grade 3 or Higher Decrease in Glucose (mmol/L)	0 percentage of participants
Axicabtagene Ciloleucel (Follicular Lymphoma)	Percentage of Participants With Decrease in Laboratory Values Reported as Grade 3 or Higher	Grade 3 or Higher Decrease in Hemoglobin (mmol/L)	33 percentage of participants
Axicabtagene Ciloleucel (Follicular Lymphoma)	Percentage of Participants With Decrease in Laboratory Values Reported as Grade 3 or Higher	Grade 3 or Higher Decrease in Albumin (g/L)	2 percentage of participants
Axicabtagene Ciloleucel (Follicular Lymphoma)	Percentage of Participants With Decrease in Laboratory Values Reported as Grade 3 or Higher	Grade 3 or Higher Decrease in Leukocytes (10^9/L)	94 percentage of participants
Axicabtagene Ciloleucel (Follicular Lymphoma)	Percentage of Participants With Decrease in Laboratory Values Reported as Grade 3 or Higher	Grade 3 or Higher Decrease in Magnesium (mmol/L)	0 percentage of participants
Axicabtagene Ciloleucel (Follicular Lymphoma)	Percentage of Participants With Decrease in Laboratory Values Reported as Grade 3 or Higher	Grade 3 or Higher Decrease in Lymphocytes (10^9/L)	99 percentage of participants
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Percentage of Participants With Decrease in Laboratory Values Reported as Grade 3 or Higher	Grade 3 or Higher Decrease in Magnesium (mmol/L)	0 percentage of participants
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Percentage of Participants With Decrease in Laboratory Values Reported as Grade 3 or Higher	Grade 3 or Higher Decrease in Neutrophils (10^9/L)	96 percentage of participants
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Percentage of Participants With Decrease in Laboratory Values Reported as Grade 3 or Higher	Grade 3 or Higher Decrease in Platelets (10^9/L)	32 percentage of participants
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Percentage of Participants With Decrease in Laboratory Values Reported as Grade 3 or Higher	Grade 3 or Higher Decrease in Albumin (g/L)	4 percentage of participants
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Percentage of Participants With Decrease in Laboratory Values Reported as Grade 3 or Higher	Grade 3 or Higher Decrease in Calcium (mmol/L)	7 percentage of participants
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Percentage of Participants With Decrease in Laboratory Values Reported as Grade 3 or Higher	Grade 3 or Higher Decrease in Glucose (mmol/L)	0 percentage of participants
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Percentage of Participants With Decrease in Laboratory Values Reported as Grade 3 or Higher	Grade 3 or Higher Decrease in Lymphocytes (10^9/L)	100 percentage of participants
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Percentage of Participants With Decrease in Laboratory Values Reported as Grade 3 or Higher	Grade 3 or Higher Decrease in Phosphate (mmol/L)	39 percentage of participants
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Percentage of Participants With Decrease in Laboratory Values Reported as Grade 3 or Higher	Grade 3 or Higher Decrease in Potassium (mmol/L)	7 percentage of participants
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Percentage of Participants With Decrease in Laboratory Values Reported as Grade 3 or Higher	Grade 3 or Higher Decrease in Sodium (mmol/L)	18 percentage of participants
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Percentage of Participants With Decrease in Laboratory Values Reported as Grade 3 or Higher	Grade 3 or Higher Decrease in Hemoglobin (mmol/L)	39 percentage of participants
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Percentage of Participants With Decrease in Laboratory Values Reported as Grade 3 or Higher	Grade 3 or Higher Decrease in Leukocytes (10^9/L)	93 percentage of participants

Secondary

Percentage of Participants With Increase in Laboratory Values Reported as Grade 3 or Higher

Percentages were rounded-off.

Time frame: Up to 85.6 months

Population: Participants in the Safety Analysis Set were analyzed.

Arm	Measure	Group	Value (NUMBER)
Axicabtagene Ciloleucel (Follicular Lymphoma)	Percentage of Participants With Increase in Laboratory Values Reported as Grade 3 or Higher	Grade 3 or Higher Increase in Sodium (mmol/L)	0 percentage of participants
Axicabtagene Ciloleucel (Follicular Lymphoma)	Percentage of Participants With Increase in Laboratory Values Reported as Grade 3 or Higher	Grade 3 or Higher Increase in Calcium (mmol/L)	1 percentage of participants
Axicabtagene Ciloleucel (Follicular Lymphoma)	Percentage of Participants With Increase in Laboratory Values Reported as Grade 3 or Higher	Grade 3 or Higher Increase in Alanine Aminotransferase (U/L)	6 percentage of participants
Axicabtagene Ciloleucel (Follicular Lymphoma)	Percentage of Participants With Increase in Laboratory Values Reported as Grade 3 or Higher	Grade 3 or Higher Increase in Creatinine (umol/L)	1 percentage of participants
Axicabtagene Ciloleucel (Follicular Lymphoma)	Percentage of Participants With Increase in Laboratory Values Reported as Grade 3 or Higher	Grade 3 or Higher Increase in Leukocytes (10^9/L)	1 percentage of participants
Axicabtagene Ciloleucel (Follicular Lymphoma)	Percentage of Participants With Increase in Laboratory Values Reported as Grade 3 or Higher	Grade 3 or Higher Increase in Direct Bilirubin (umol/L)	2 percentage of participants
Axicabtagene Ciloleucel (Follicular Lymphoma)	Percentage of Participants With Increase in Laboratory Values Reported as Grade 3 or Higher	Grade 3 or Higher Increase in Alkaline Phosphatase (U/L)	0 percentage of participants
Axicabtagene Ciloleucel (Follicular Lymphoma)	Percentage of Participants With Increase in Laboratory Values Reported as Grade 3 or Higher	Grade 3 or Higher Increase in Glucose (mmol/L)	9 percentage of participants
Axicabtagene Ciloleucel (Follicular Lymphoma)	Percentage of Participants With Increase in Laboratory Values Reported as Grade 3 or Higher	Grade 3 or Higher Increase in Hemoglobin (mmol/L)	0 percentage of participants
Axicabtagene Ciloleucel (Follicular Lymphoma)	Percentage of Participants With Increase in Laboratory Values Reported as Grade 3 or Higher	Grade 3 or Higher Increase in Magnesium (mmol/L)	3 percentage of participants
Axicabtagene Ciloleucel (Follicular Lymphoma)	Percentage of Participants With Increase in Laboratory Values Reported as Grade 3 or Higher	Grade 3 or Higher Increase in Aspartate Aminotransferase (U/L)	4 percentage of participants
Axicabtagene Ciloleucel (Follicular Lymphoma)	Percentage of Participants With Increase in Laboratory Values Reported as Grade 3 or Higher	Grade 3 or Higher Increase in Potassium (mmol/L)	1 percentage of participants
Axicabtagene Ciloleucel (Follicular Lymphoma)	Percentage of Participants With Increase in Laboratory Values Reported as Grade 3 or Higher	Grade 3 or Higher Increase in Lymphocytes (10^9/L)	0 percentage of participants
Axicabtagene Ciloleucel (Follicular Lymphoma)	Percentage of Participants With Increase in Laboratory Values Reported as Grade 3 or Higher	Grade 3 or Higher Increase in Urate (mmol/L)	13 percentage of participants
Axicabtagene Ciloleucel (Follicular Lymphoma)	Percentage of Participants With Increase in Laboratory Values Reported as Grade 3 or Higher	Grade 3 or Higher Increase in Bilirubin (umol/L)	4 percentage of participants
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Percentage of Participants With Increase in Laboratory Values Reported as Grade 3 or Higher	Grade 3 or Higher Increase in Urate (mmol/L)	25 percentage of participants
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Percentage of Participants With Increase in Laboratory Values Reported as Grade 3 or Higher	Grade 3 or Higher Increase in Hemoglobin (mmol/L)	0 percentage of participants
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Percentage of Participants With Increase in Laboratory Values Reported as Grade 3 or Higher	Grade 3 or Higher Increase in Leukocytes (10^9/L)	0 percentage of participants
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Percentage of Participants With Increase in Laboratory Values Reported as Grade 3 or Higher	Grade 3 or Higher Increase in Lymphocytes (10^9/L)	0 percentage of participants
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Percentage of Participants With Increase in Laboratory Values Reported as Grade 3 or Higher	Grade 3 or Higher Increase in Alanine Aminotransferase (U/L)	21 percentage of participants
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Percentage of Participants With Increase in Laboratory Values Reported as Grade 3 or Higher	Grade 3 or Higher Increase in Alkaline Phosphatase (U/L)	4 percentage of participants
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Percentage of Participants With Increase in Laboratory Values Reported as Grade 3 or Higher	Grade 3 or Higher Increase in Aspartate Aminotransferase (U/L)	11 percentage of participants
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Percentage of Participants With Increase in Laboratory Values Reported as Grade 3 or Higher	Grade 3 or Higher Increase in Bilirubin (umol/L)	11 percentage of participants
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Percentage of Participants With Increase in Laboratory Values Reported as Grade 3 or Higher	Grade 3 or Higher Increase in Calcium (mmol/L)	0 percentage of participants
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Percentage of Participants With Increase in Laboratory Values Reported as Grade 3 or Higher	Grade 3 or Higher Increase in Creatinine (umol/L)	0 percentage of participants
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Percentage of Participants With Increase in Laboratory Values Reported as Grade 3 or Higher	Grade 3 or Higher Increase in Direct Bilirubin (umol/L)	11 percentage of participants
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Percentage of Participants With Increase in Laboratory Values Reported as Grade 3 or Higher	Grade 3 or Higher Increase in Glucose (mmol/L)	21 percentage of participants
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Percentage of Participants With Increase in Laboratory Values Reported as Grade 3 or Higher	Grade 3 or Higher Increase in Magnesium (mmol/L)	4 percentage of participants
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Percentage of Participants With Increase in Laboratory Values Reported as Grade 3 or Higher	Grade 3 or Higher Increase in Sodium (mmol/L)	0 percentage of participants
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Percentage of Participants With Increase in Laboratory Values Reported as Grade 3 or Higher	Grade 3 or Higher Increase in Potassium (mmol/L)	0 percentage of participants

Secondary

PFS Per Lugano Classification by Investigator Assessment

PFS was defined as the time from the axicabtagene ciloleucel infusion date to the date of disease progression per Lugano classification or death from any cause. PD is defined in OM 6. KM estimates were used for analysis.

Time frame: Up to 85.6 months

Population: Participants in Full Analysis Set were analyzed.

Arm	Measure	Value (MEDIAN)
Axicabtagene Ciloleucel (Follicular Lymphoma)	PFS Per Lugano Classification by Investigator Assessment	58.2 months
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	PFS Per Lugano Classification by Investigator Assessment	NA months

Secondary

Progression-free Survival (PFS) Per Lugano Classification by Central Assessment

Time frame: Up to 85.6 months

Population: Participants in the Full Analysis Set with available data were analyzed.

Arm	Measure	Value (MEDIAN)
Axicabtagene Ciloleucel (Follicular Lymphoma)	Progression-free Survival (PFS) Per Lugano Classification by Central Assessment	40.2 months
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Progression-free Survival (PFS) Per Lugano Classification by Central Assessment	18.3 months

Secondary

Time to Next Therapy

Time from axicabtagene ciloleucel infusion date to the start of the subsequent new lymphoma therapy or death from any cause. KM estimates were used for analysis.

Time frame: Up to 85.6 months

Population: Participants in the Full Analysis Set were analyzed.

Arm	Measure	Value (MEDIAN)
Axicabtagene Ciloleucel (Follicular Lymphoma)	Time to Next Therapy	NA months
Axicabtagene Ciloleucel (Marginal Zone Lymphoma)	Time to Next Therapy	NA months

Source: ClinicalTrials.gov · Data processed: Sep 18, 2026

A Study of Axicabtagene Ciloleucel in Participants With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Conditions

Brief summary

Detailed description

Related papers

Interventions

Sponsors

Study design

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Countries

Participant flow

Recruitment details

Pre-assignment details

Participants by arm

Withdrawals & dropouts

Baseline characteristics

Adverse events

Outcome results

Objective Response Rate (ORR): Percentage of Participants With Objective Response Per the Lugano Classification by Central Assessment

DOR by Investigator Assessment

Duration of Response (DOR) by Central Assessment

Levels of Anti-CD19 CAR T Cells in Blood

Levels of Serum C-Reactive Protein (CRP)

Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha

Levels of Serum Ferritin, Serum ICAM-1, Serum IL-2 R Alpha, Serum Perforin and Serum VCAM-1

ORR: Percentage of Participants With OR Per the Lugano Classification by Central Assessment Among Participants With 3 or More Lines of Prior Therapy

ORR: Percentage of Participants With OR Per the Lugano Classification by Investigator Assessment

Overall Survival (OS)

Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)

Percentage of Participants With Antibodies Against Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells

Percentage of Participants With Best Overall Response (BOR) Per the Lugano Classification by Central Assessment

Percentage of Participants With BOR Per the Lugano Classification by Investigator Assessment

Percentage of Participants With CR Per Lugano Classification by Central Assessment Among Participants With 3 or More Lines of Prior Therapy

Percentage of Participants With CR Per the Lugano Classification by Central Assessment

Percentage of Participants With Decrease in Laboratory Values Reported as Grade 3 or Higher

Percentage of Participants With Increase in Laboratory Values Reported as Grade 3 or Higher

PFS Per Lugano Classification by Investigator Assessment

Progression-free Survival (PFS) Per Lugano Classification by Central Assessment

Time to Next Therapy